Zhang Shui-xing, Qiu Qian-hui, Chen Wen-bo, Liang Chang-hong, Huang Biao
Department of Radiology, Guangdong General Hospital, Guangzhou, Guangdong, PR China.
Cell Physiol Biochem. 2014;33(5):1484-97. doi: 10.1159/000358713. Epub 2014 May 9.
Previous work has proposed that celecoxib may be able to enhance the effects of radiotherapy. However, the underlying mechanism of this activity has not yet been determined.
The cell colony formation assay after the combination of celecoxib and radiation treatment was done on C666-1, CNE-1 and CNE-2 nasopharyngeal carcinoma cells, which expressed different COX-2 levels. Moreover, COX-2 knocked down or overexpressed cells were developed, and apoptosis and cell cycle analysis were performed.
Celecoxib enhances radiation cytotoxicity in C666-1 and CNE-1 nasopharyngeal carcinoma cells that expressed high COX-2 but not in CNE-2 cells that expressed low COX-2. The radiosensitization of celecoxib in C666-1 cells disappeared after the COX-2 knocked down, while the CNE-2 cells were radiosensitized by celecoxib after the transfection of COX-2. Moreover, celecoxib enhanced radiation-induced G2-M phase arrest was observed in some of the tested cells. Furthermore, we found that the radiosensitivity of celecoxib in nasopharyngeal carcinoma was correlated with the apoptosis induction. Additionally, the combination of celecoxib (25 mg/kg) and radiation (6 Gy) treatment significantly reduced tumor volume in C666-1 and CNE-2 nasopharyngeal carcinoma xenograft models.
These results indicate that the combination of celecoxib and radiation treatment has potential application in radiotherapy, and these effects may be attributable to the G2-M cell phase arrest and enhancement of cell apoptosis.
先前的研究表明塞来昔布可能能够增强放射治疗的效果。然而,这一作用的潜在机制尚未确定。
对表达不同COX-2水平的C666-1、CNE-1和CNE-2鼻咽癌细胞进行塞来昔布与放射治疗联合后的细胞集落形成试验。此外,构建了COX-2基因敲低或过表达的细胞,并进行了凋亡和细胞周期分析。
塞来昔布可增强高表达COX-2的C666-1和CNE-1鼻咽癌细胞的放射细胞毒性,但对低表达COX-2的CNE-2细胞无此作用。COX-2基因敲低后,塞来昔布在C666-1细胞中的放射增敏作用消失,而转染COX-2后,CNE-2细胞对塞来昔布产生了放射增敏作用。此外,在部分受试细胞中观察到塞来昔布增强了辐射诱导的G2-M期阻滞。此外,我们发现塞来昔布在鼻咽癌中的放射敏感性与诱导凋亡相关。另外,塞来昔布(25 mg/kg)与放射(6 Gy)联合治疗显著减小了C666-1和CNE-2鼻咽癌异种移植模型中的肿瘤体积。
这些结果表明塞来昔布与放射治疗联合在放射治疗中具有潜在应用价值,这些作用可能归因于G2-M期细胞阻滞和细胞凋亡增强。